구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Temozolomide (TMZ) |
Overview Company | EMD Serono |
Overview Modality | ADC |
Overview Target | Advanced Solid Malignancies |
Overview Indication | Advanced Solid Malignancies |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | SN-38 for the treatment of glioblastoma: Engi |
Technology Linker | linker to conjugate a vascular endothelial growth factor-targeting antibody with the c |
MoA Mechanism | targets were involved in multiple biological processes, cellular components, molecular functions, and signaling pathway |
MoA Biomarker | biomarkers for nitrosative stress, and apoptosis using western blot analysis, flow cytometry and AnnexinV/PI |
PK/PD Half-life | 5 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Ketogenic Diet: A Metabolic Key to Overcoming Cancer Therapy Resistance.. The ketogenic diet (KD), characterized by very low carbohydrate intake, moderate protein consumption, and variable fat content depending on the specific dietary protocol, has emerged as a promising metabolic approach in oncology. Although significant progress has been achieved in chemotherapy and immunotherapy for cancer tre… |
Toxicology CRS | Reported |
Clinical Safety signal | Ketogenic Diet: A Metabolic Key to Overcoming Cancer Therapy Resistance.. The ketogenic diet (KD), characterized by very low carbohydrate intake, moderate protein consumption, and variable fat content depending on the specific dietary protocol, has emerged as a promising metabolic approach in oncology. Although significant progress has been achieved in chemotherapy and immunotherapy for cancer tre… |
Clinical Reported PFS | 10.5 |
Clinical Reported OS | 29.6 |
Clinical Result source | ClinicalTrials.gov NCT00302159 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00302159 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Temozolomide (TMZ) |
Overview Company | EMD Serono |
Overview Modality | ADC |
Overview Target | Advanced Solid Malignancies |
Overview Indication | Advanced Solid Malignancies |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | SN-38 for the treatment of glioblastoma: Engi |
Technology Linker | linker to conjugate a vascular endothelial growth factor-targeting antibody with the c |
MoA Mechanism | targets were involved in multiple biological processes, cellular components, molecular functions, and signaling pathway |
MoA Biomarker | biomarkers for nitrosative stress, and apoptosis using western blot analysis, flow cytometry and AnnexinV/PI |
PK/PD Half-life | 5 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Ketogenic Diet: A Metabolic Key to Overcoming Cancer Therapy Resistance.. The ketogenic diet (KD), characterized by very low carbohydrate intake, moderate protein consumption, and variable fat content depending on the specific dietary protocol, has emerged as a promising metabolic approach in oncology. Although significant progress has been achieved in chemotherapy and immunotherapy for cancer tre… |
Toxicology CRS | Reported |
Clinical Safety signal | Ketogenic Diet: A Metabolic Key to Overcoming Cancer Therapy Resistance.. The ketogenic diet (KD), characterized by very low carbohydrate intake, moderate protein consumption, and variable fat content depending on the specific dietary protocol, has emerged as a promising metabolic approach in oncology. Although significant progress has been achieved in chemotherapy and immunotherapy for cancer tre… |
Clinical Reported PFS | 10.5 |
Clinical Reported OS | 29.6 |
Clinical Result source | ClinicalTrials.gov NCT00302159 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT00302159 |
추천 비교
추천 비교